![]() BMS-751324 structure
|
Common Name | BMS-751324 | ||
---|---|---|---|---|
CAS Number | 948842-66-8 | Molecular Weight | 694.628 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C32H35N6O10P | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of BMS-751324BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM; BMS-751324 is effectively bioconverted into parent drug BMS-582949 in vivo by alkaline phosphatase and esterase in a stepwise manner; demonstrates similar efficacy in rat LPS-induced TNFα pharmacodynamic model and rat adjuvant arthritis model compared with BMS-582949; BMS-751324 is indeed effective in addressing the pH-dependent absorption issue associated with BMS-582949. |
Name | Bms-751324 |
---|---|
Synonym | More Synonyms |
Description | BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM; BMS-751324 is effectively bioconverted into parent drug BMS-582949 in vivo by alkaline phosphatase and esterase in a stepwise manner; demonstrates similar efficacy in rat LPS-induced TNFα pharmacodynamic model and rat adjuvant arthritis model compared with BMS-582949; BMS-751324 is indeed effective in addressing the pH-dependent absorption issue associated with BMS-582949. |
---|---|
References | References 1. Liu C, et al. J Med Chem. 2015 Oct 8;58(19):7775-84. View Related Products by Target p38 MAPK |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C32H35N6O10P |
Molecular Weight | 694.628 |
Exact Mass | 694.215210 |
LogP | 1.22 |
Index of Refraction | 1.676 |
Benzeneacetic acid, 4-(phosphonooxy)-, α-[[[[[[4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbonyl]propylamino]carbonyl]oxy]methyl] ester |
Bms-751324 |
({[(4-{[5-(Cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl](propyl)carbamoyl}oxy)methyl [4-(phosphonooxy)phenyl]acetate |